Latest Conference Articles

Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

In long-term follow-up of KEEPsAKE 1 and 2, risankizumab maintained joint, skin, pain, and axial responses in patients with PsA through 244 weeks.

However, a notable higher rate of treatment-related adverse events warrants caution.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.